Patients with acutely decompensated cirrhosis frequently present a paradoxical immune state characterized by persistent systemic inflammation together with severe immunosuppression. This dysfunctional immune response increases their susceptibility to bacterial infections, one of the main precipitants of ACLF, a syndrome characterized by multi-organ systems failure and high short-term mortality.
To better understand the molecular mechanisms underlying immune dysfunction in these patients, researchers at EF CLIF from Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques Pi i Sunyer (IDIBAPS) performed a comprehensive lipidomics analysis of 308 plasma samples longitudinally collected from 93 patients with acutely decompensated cirrhosis with and without ACLF, as well as from healthy subjects. Using liquid chromatography coupled to tandem mass spectrometry, researchers profiled 98 immunomodulatory lipid mediators and integrated these findings with gene expression, flow cytometry, and functional immune cell analyses.
The study identified the linoleic acid-derived leukotoxin 9,10-DiHOME as the only lipid mediator specifically elevated in patients who developed infections and ACLF. Levels of 9,10-DiHOME closely tracked disease severity and peaked during episodes of infection and organ failure.
“Previous results from our group showed that patients with acutely decompensated cirrhosis presented an altered lipidomic profile. This condition would disrupt the lipid mediator composition, which is a well-known modulator of the immune response. Therefore, functional characterization of the immune system under this altered environment was needed to better understand the impaired immune response”, said first author in the paper Bryan J. Contreras, predoctoral researcher at IDIBAPS.
Functional studies revealed that 9,10-DiHOME critically impaired the defensive capacity of circulating immune cells. In polymorphonuclear leukocytes—rapid-response components of the innate immune system—the lipid mediator reduced phagocytosis, degranulation, and respiratory burst activity, all essential mechanisms required for pathogen clearance. In mononuclear leukocytes—specialized immune cells responsible for targeted, long-term defense—9,10-DiHOME induced the expression of MerTK, a marker strongly associated with immunosuppressive phenotypes, while simultaneously reducing inflammatory cytokine responses and disrupting mitochondrial and autophagic functions.
“These findings provide a mechanistic explanation for the immune paralysis observed in patients with advanced cirrhosis”, said Contreras. “Our data indicate that 9,10-DiHOME not only accumulates in the most severe stages of the disease, but actively suppresses immune cell defensive responses against pathogens”, he added.
Researchers also investigated the origin of 9,10-DiHOME accumulation and found increased expression of soluble epoxide hydrolase, the enzyme responsible for its biosynthesis, in leukocytes from patients with acutely decompensated cirrhosis. Experimental studies in a murine model of cirrhosis and peritonitis further demonstrated that pharmacological inhibition of soluble epoxide hydrolase restored immune responses in macrophages and significantly reduced immunosuppressive markers in the liver and peritoneal cavity.
“These findings highlight the relevance of lipids as drivers of immunosuppression and open new therapeutic avenues to prevent and treat cirrhosis-associated immune dysfunction”, said senior author Joan Clària, Director of the Grifols Chair and Head of Translational Operations at EF CLIF, senior consultant at the Biochemistry and Molecular Genetics Service of the Hospital Clínic of Barcelona, and Group Leader of the Inflammation and Liver Disease group at IDIBAPS, Spain.
The study suggests that the CYP450–soluble epoxide hydrolase metabolic axis may represent a previously unrecognized driver of immune suppression in advanced cirrhosis. By blocking the generation of 9,10-DiHOME, soluble epoxide hydrolase inhibition could potentially restore immune competence and reduce susceptibility to life-threatening infections.
Importantly, soluble epoxide hydrolase inhibitors are already being explored in clinical trials for metabolic, vascular, and neurological diseases, raising the possibility that these compounds could eventually be repurposed for patients with advanced liver disease.
Beyond identifying a prognostic biomarker, the study also provides insight into how chronic inflammation and immune suppression coexist in acutely decompensated cirrhosis. Researchers showed that 9,10-DiHOME acts, at least in part, through activation of PPARγ signaling pathways known to regulate macrophage polarization and inflammatory responses.
These findings also support previous evidence indicating that immunosuppressive MerTK-positive monocytes and macrophages play a central role in defective antimicrobial responses in ACLF. By inducing these immunosuppressive phenotypes, 9,10-DiHOME may contribute directly to impaired pathogen clearance and progression toward organ failure.
“The next steps should focus on moving from association toward mechanistic validation. In this context, integrating lipidomics with functional immunometabolism approaches could be particularly informative. Characterizing how lipid mediators such as 9,10-DiHOME alter the metabolic programs of specific immune cell subsets in patients with advanced cirrhosis could help determine whether these mediators directly contribute to immune paralysis and increased susceptibility to infections”, said senior co-corresponding author Cristina López-Vicario from IDIBAPS.
Although the study was observational and many mechanistic questions remain open, it represents one of the most comprehensive investigations to date of lipid mediator dysregulation in advanced cirrhosis. By combining longitudinal lipidomics with immune functional studies and experimental models, the work identifies a biologically plausible pathway linking metabolic alterations to immune paralysis and poor clinical outcomes.
“Our findings position the inhibition of soluble epoxide hydrolase as a promising therapeutic strategy to prevent immunosuppression and bacterial infections in patients with decompensated cirrhosis”, concluded López-Vicario. “Future studies will be required to determine whether modulation of this pathway can safely restore immune competence and improve outcomes in patients at high risk of ACLF”.
Other authors in the study are Berta Romero-Grimaldo, Maria Belén Sánchez-Rodríguez, Mireia Casulleras, Marta Duran-Güell, Maria Papp, Richard Moreau, and Jonel Trebicka.
Bryan J. Contreras, Joan Clària and Cristina López-Vicario are supported by Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Spain.
Contreras BJ, Romero-Grimaldo B, Sánchez-Rodríguez MB, Casulleras M, Duran-Güell M, Papp M, Moreau R, Trebicka J, Clària J, López-Vicario C; MICROB-PREDICT investigators. The linoleic acid-derived leukotoxin 9,10-DiHOME drives immunosuppression in patients with acute-on-chronic liver failure. Hepatology 2026. E pub ahead of print. DOI: 10.1097/hep.0000000000001770
This study received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 847949.
European Foundation for the Study of
Chronic Liver Failure
Avinguda Diagonal 477, 11th floor
08036 Barcelona, Spain
Tel: +34 93 227 14 00
Email: Send us an email
© 2025 European Foundation for the Study of Chronic Liver Failure

| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |